Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5193525
Max Phase: Preclinical
Molecular Formula: C53H70N18O9S2
Molecular Weight: 1167.39
Associated Items:
ID: ALA5193525
Max Phase: Preclinical
Molecular Formula: C53H70N18O9S2
Molecular Weight: 1167.39
Associated Items:
Canonical SMILES: CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H]1CSSC[C@H](C(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@@H](C)NC1=O
Standard InChI: InChI=1S/C53H70N18O9S2/c1-28-45(74)67-41(22-34-24-59-27-63-34)50(79)68-39(20-30-15-16-31-9-3-4-10-32(31)19-30)48(77)66-38(14-8-18-61-53(57)58)47(76)69-40(21-33-23-62-36-12-6-5-11-35(33)36)49(78)70-42(44(54)73)25-81-82-26-43(51(80)64-28)71-46(75)37(65-29(2)72)13-7-17-60-52(55)56/h3-6,9-12,15-16,19,23-24,27-28,37-43,62H,7-8,13-14,17-18,20-22,25-26H2,1-2H3,(H2,54,73)(H,59,63)(H,64,80)(H,65,72)(H,66,77)(H,67,74)(H,68,79)(H,69,76)(H,70,78)(H,71,75)(H4,55,56,60)(H4,57,58,61)/t28-,37+,38+,39-,40+,41+,42-,43-/m1/s1
Standard InChI Key: SVIPPJOIJYVFMK-NHAYSBRJSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1167.39 | Molecular Weight (Monoisotopic): 1166.5015 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Gimenez LE, Noblin TA, Williams SY, Mullick Bagchi S, Ji RL, Tao YX, Jeppesen CB, Conde-Frieboes KW, Sawyer TK, Grieco P, Cone RD.. (2022) Demonstration of a Common DPhe7 to DNal(2')7 Peptide Ligand Antagonist Switch for Melanocortin-3 and Melanocortin-4 Receptors Identifies the Systematic Mischaracterization of the Pharmacological Properties of Melanocortin Peptides., 65 (8.0): [PMID:35404053] [10.1021/acs.jmedchem.1c01295] |
Source(1):